# data[].attributes.headline
Can hair loss be the next GLP-1 moment? 

# data[].attributes.subject
Can hair loss be the next GLP-1 moment? 

# data[].attributes.body
Hair loss is emerging as a major “medicine–aesthetics” opportunity similar to GLP‑1s, with huge unmet need, high willingness to pay, and long‑stagnant drug innovation.

New approaches are finally moving beyond minoxidil and finasteride: Pelage’s topical PP405 reactivates hair follicle stem cells via lactate‑linked metabolism and showed >20% hair‑density gains in some men in a Phase 2a trial, while Veradermics’ extended‑release oral minoxidil (VDPHL01) aims for consistent exposure with fewer cardiovascular risks and has produced strong hair‑count and patient‑reported improvements so far.

In immune‑mediated alopecia areata, Nektar’s rezpegaldesleukin expands regulatory T cells to reset immune balance, more than doubling hair regrowth versus placebo with a favourable safety profile compared to JAK inhibitors.

Cell‑based regeneration is also advancing: Shiseido’s autologous dermal sheath cup cell therapy is already offered in Japan, and dermal papilla cell–based strategies could ultimately scale to generate new follicles for broader hair restoration.

Overall, the field is shifting from incremental, symptom‑focused drugs toward regenerative, immune‑modulating, and reformulated therapies that could deliver durable regrowth, potentially making hair loss the next breakout “lifestyle” drug category if even one approach proves both effective and safe at scale.

# data[].attributes.attachment_link.description
Hair loss affects millions, and a new wave of therapies — from drugs to cell-based treatments — could finally offer safe, effective, and lasting solutions.

# data[].attributes.headline
GSK Hands Back Rights to Wave’s Pioneering RNA Editing Drug for Alpha‑1 Antitrypsin Deficiency

# data[].attributes.subject
GSK Hands Back Rights to Wave’s Pioneering RNA Editing Drug for Alpha‑1 Antitrypsin Deficiency

# data[].attributes.body
GSK is returning global rights to Wave Life Sciences’ pioneering RNA editing drug WVE‑006, which targets alpha‑1 antitrypsin deficiency (AATD), handing full control of the program back to Wave. Wave says the decision is not driven by new data but by an agreement that a small biotech is better placed than GSK to rapidly advance a rare‑disease therapy, especially as GSK’s respiratory focus is on larger‑population diseases.

WVE‑006, the first RNA editing therapy to reach human testing, has shown it can restore production of functional alpha‑1 antitrypsin protein in patients, supporting Wave’s argument that it could potentially offer a “functional cure,” though investors have questioned the strength of the effect and remain cautious, particularly after a rival Korro Bio program in AATD was discontinued for lackluster potency. Wave plans to accelerate regulatory engagement, aiming for discussions with the FDA about a potential accelerated approval pathway by mid‑year and positioning WVE‑006 as a barometer for whether RNA editing can become a viable, safer alternative to DNA editing in genetic medicine.

# data[].attributes.attachment_link.title
GSK walks away from pioneering Wave RNA editing drug

# data[].attributes.attachment_link.description
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

# data[].attributes.headline
Oral AVIL Inhibitor Shows Promise Against Glioblastoma in Preclinical Mouse Models

# data[].attributes.subject
Oral AVIL Inhibitor Shows Promise Against Glioblastoma in Preclinical Mouse Models

# data[].attributes.body
Researchers have identified a small molecule, “compound A,” that significantly shrinks glioblastoma tumors in multiple mouse models, including temozolomide‑resistant disease, after oral dosing and with no evident toxicity.

The compound inhibits advillin (AVIL), an actin‑binding protein previously thought to be an undruggable target, and shows particular activity against glioblastoma stem cells, suggesting tumors may find it harder to develop resistance.

Because compound A crosses the blood–brain barrier and hits several key translational benchmarks in preclinical testing, a spinout, Avil Therapeutics, is now optimizing it into a pill formulation with the aim of starting first‑in‑human trials in one to two years, though the researchers stress it is still far from a cure and further work is needed to understand potential resistance.

# data[].attributes.attachment_link.title
Pharmacological investigation of bergapten isolated from Glehnia littoralis against periodontitis - Scientific Reports

# data[].attributes.attachment_link.description
Periodontitis is a periodontal disease that causes tooth loss in severe cases due to chronic inflammation. The role of ER stress in this process of periodontal inflammation has not been identified. Glehnia littoralis has been used to relieve inflammation in traditional Chinese medicine, and the effect of bergapten, a compound isolated from G. littoralis, on ER stress during the progression of periodontitis was evaluated. The efficacy of bergapten was evaluated in silico and in vitro using human periodontal ligament cells stimulated with Porphyromonas gingivalis-lipopolysaccharides (PG-LPS). The effects of bergapten were also demonstrated in two in vivo model on PG-LPS- and ligature-induced periodontitis animal models. In silico simulation revealed that bergapten bound to the active site and downregulated the gene expression levels of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1β, which are major inflammatory cytokines in periodontitis. Osteoblast differentiation was induced in human periodontal ligament cells stimulated with PG-LPS. These effects were confirmed to occur through the regulation of ER stress by bergapten. An in vivo study was conducted to support these in vitro results, and bergapten alleviated inflammatory infiltration and inflammatory cytokine expression levels, along with restoring periodontitis-induced periodontal tissue loss. This study reveals the novel physiological activity of bergapten and suggests its potential as a new periodontitis therapeutic agent that can reduce the side effects caused by various surgical treatments and therapies used to treat periodontitis.

# data[].attributes.attachment_link.readable_text
Author notes

These authors contributed equally: Jin-Ming Liu, Yan-Lin Zhang, Fang Guo, Bin-Wu Li.

Authors and Affiliations

1. Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong-Hong Kong Joint Laboratory for Psychiatric Disorders, Guangdong Province Key Laboratory of Psychiatric Disorders, Guangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, P.R. China

Jin-Ming Liu, Fang Guo, Bin-Wu Li, Hu Chen & Xiong Cao

2. Guangzhou Key Laboratory of Forensic Multi-Omics for Precision Identification, School of Forensic Medicine, Southern Medical University, Guangzhou, 510515, P.R. China

Yan-Lin Zhang, Yuye Mo, Jiangwei Kong & Xiaohui Tan

3. Department of Psychiatry, The third people's Hospital of Foshan, Foshan, 528000, P.R. China

Weibin Wu

Contributions

X. Cao, W. Wu, X. Tan and J. Liu conceived and designed the study. J. Liu, Y. Zhang, F. Guo, B. Li performed the experiments and analyzed the data. H. Chen, Y. Mo, J. Kong participate in the experiments. J. Liu, X. Cao wrote the manuscript. All authors provided the inputs and reviewed the manuscript.

Corresponding authors

Correspondence to Xiaohui Tan, Weibin Wu or Xiong Cao.

# data[].attributes.attachment_link.title
Treatment with perampanel alleviates depression-like behavior in mice via modulating GluN2B expression to improve excitatory synaptic transmission - Translational Psychiatry

# data[].attributes.attachment_link.description
Antidepressants that target the glutamatergic system, such as ketamine, have shown promising results. However, the contribution of other potential medications targeting the glutamate system to depression is unclear. Our research found that perampanel can exert a rapid and long-lasting antidepressant effect to improve the behavior of chronic social defeat stress (CSDS) depression susceptible mice.

# data[].attributes.attachment_link.readable_text
Scientists have developed a nasal spray vaccine that blocks bird flu infection in animals and works even when standard flu shots fall short. By stopping the virus in the nose and lungs, it could reduce both severe disease and transmission. Credit: Shutterstock

H5N1 avian influenza, often called bird flu, was first identified in the United States in 2014. Since then, the virus has moved beyond wild birds, spreading into farm animals and eventually infecting people. More than 70 human cases have been reported in the U.S. since 2022, including two deaths. Because the virus is still circulating widely among animals, scientists warn that it has ongoing chances to adapt in ways that could allow it to spread more easily between humans, raising concerns about a future pandemic.

To reduce the risk of widespread transmission, researchers at Washington University School of Medicine in St. Louis developed a vaccine delivered through the nose rather than by injection. When tested in hamsters and mice, the intranasal vaccine triggered strong immune responses and prevented infection after exposure to H5N1.

The team also addressed a key challenge facing bird flu vaccines. Immunity from prior seasonal flu infections or vaccinations can sometimes weaken responses to new flu vaccines. In this case, researchers found that the nasal vaccine remained effective even in animals with existing flu immunity.

The findings were published Jan. 30 in Cell Reports Medicine.

"This particular version of bird flu has been around for some time, but the unique and totally unexpected event where it jumped across species into dairy cows in the United States was a clear sign that we should prepare for the event that a pandemic may occur," said Jacco Boon, PhD, a professor in the WashU Medicine John T. Milliken Department of Medicine and co-senior author of the study. "Our vaccine to the nose and upper airway -- not the shot-in-the-arm vaccine people are used to -- can protect against upper respiratory infection as well as severe disease. This could provide better protection against transmission because it protects against infection in the first place."
Updating Bird Flu Vaccine Technology
Although a bird flu vaccine already exists, it was designed using older virus strains, may not work well against current versions of H5N1, and is not widely available. To create a more effective option, Boon and his colleagues relied on nasal vaccine technology previously developed at WashU Medicine by study co-authors Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and David T. Curiel, MD, PhD, a professor of radiation oncology.

A COVID-19 vaccine built on this same platform has been available in India since 2022 and received approval for clinical testing in the U.S. last year.
Designing an Immune Response That Matches the Virus
For a vaccine to work well, the immune system must be able to quickly recognize the virus it targets. To achieve this, Boon and co-author Eva-Maria Strauch, PhD, an associate professor of medicine with expertise in antivirals and protein design, selected proteins from H5N1 strains known to infect humans. Using shared features of these viral proteins, they engineered an optimized antigen, the portion of the virus that prompts an immune response.

That antigen was inserted into a harmless, non-replicating adenovirus, which serves as a delivery system for the vaccine. This method of antigen design and adenovirus delivery closely mirrors the approach used for the COVID-19 nasal vaccine.
Strong Protection in Animal Studies
When researchers tested the nasal vaccine in hamsters and mice, they observed near-complete protection against H5N1 infection. As expected, existing seasonal flu vaccines offered little defense against bird flu. In both animal models, the nasal spray vaccine provided stronger protection than the same vaccine delivered by a traditional intramuscular injection.

Notably, the vaccine remained highly effective even when administered at low doses and followed by high levels of virus exposure.
Blocking Infection in the Nose and Lungs
Delivering the vaccine through the nose produced strong immune responses throughout the body, with particularly high activity in the nasal passages and respiratory tract. Boon noted that this approach offers a major advantage over injected vaccines by providing better protection in the nose and lungs, which likely reduces both severe illness and the spread of infection.

"We've shown that this nasal vaccine delivery platform we conceived, designed and conducted initial testing on at WashU Medicine can prevent H5N1 infection from taking hold in the nose and lungs," said Diamond, the study's co-senior author. "Delivering vaccine directly to the upper airway where you most need protection from respiratory infection could disrupt the cycle of infection and transmission. That's crucial to slowing the spread of infection for H5N1 as well as other flu strains and respiratory infections."

In additional experiments, the researchers examined whether immunity from previous flu infections or vaccinations would interfere with the H5N1 vaccine's performance. They found that the nasal vaccine continued to provide strong protection even when prior flu immunity was present. This is an important factor for real-world use, since most people, except young children, already have immune memory from past influenza exposure.
Next Steps for the Nasal Vaccine
The research team plans to conduct further studies in animals and in organoids that model human immune tissue. They are also working on updated versions of the vaccine designed to further reduce the influence of prior seasonal flu immunity and to enhance antiviral responses.

This study was supported by the Cooperative Center for Human Immunology (U19AI181103) and the Center for Research on Structural Biology of Infectious Diseases (75N93022C00035).

The Boon laboratory has received funding from Novavax Inc for the development of an influenza virus vaccine and unrelated funding support from AbbVie Inc. M.S.D. is a consultant for or serves on the Scientific Advisory Board of Inbios, IntegerBio, Akagera Medicines, GlaxoSmithKline, Merck, and Moderna. The Diamond laboratory has received unrelated funding support through sponsored research agreements from Moderna.

# data[].attributes.attachment_link.keywords[]
influenza; bird flu; infectious diseases; allergy; workplace health; diseases and conditions; pharmaceuticals; cold and flu

# data[].attributes.attachment_link.title
New nasal vaccine shows strong protection against H5N1 bird flu

# data[].attributes.attachment_link.description
As bird flu continues to circulate in animals and spill over into humans, researchers are racing to stop it before it adapts to spread widely between people. A new nasal spray vaccine showed strong protection against H5N1 in animal tests, outperforming traditional flu shots.

# data[].attributes.attachment_link.title
Blockbuster weight loss drugs like Ozempic deliver big results but face big questions

# data[].attributes.attachment_link.description
Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can lead to substantial weight loss in people with obesity. But while the results are impressive, researchers caution that most trials were funded by drugmakers, long term safety data are still limited, and side effects such as nausea are common.

# data[].attributes.headline
Akari files new patent and advances second ADC targeting CEACAM5

# data[].attributes.subject
Akari files new patent and advances second ADC targeting CEACAM5

# data[].attributes.attachment_link.title
Akari files new patent and advances second ADC targeting CEACAM5 - PharmaTimes

# data[].attributes.attachment_link.description
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

# data[].attributes.headline
Strong clinical data for Breye lead asset danegaptide

# data[].attributes.subject
Strong clinical data for Breye lead asset danegaptide

# data[].attributes.attachment_link.title
Strong clinical data for Breye lead asset danegaptide - PharmaTimes

# data[].attributes.attachment_link.description
Oral candidate shows favourable safety profile and signs of clinical activity in NPDR

# data[].attributes.headline
Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials

# data[].attributes.subject
Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials

# data[].attributes.attachment_link.readable_text
Re:Cognition Health, a global leader in brain and memory health research, and Cera - Europe's largest digital‑first home healthcare provider - have announced a new collaboration designed to expand access to Alzheimer's and neurodegenerative clinical trials and support more people to take part earlier in their health journey.

The collaboration brings together Re:Cognition Health's specialist brain health clinics and clinical trial expertise with Cera's 2.5 million monthly home care visits, creating new pathways for individuals who may benefit from advanced assessment and research opportunities to be identified and supported.

By linking care in the home with specialist research centres, this collaboration aims to ensure that more people can be offered the opportunity to take part in clinical trials, helping them access the latest advances in diagnosis and treatment whilst contributing to the development of future treatments.

Re:Cognition Health has played a pivotal role in the development of pioneering Alzheimer's treatments, including lecanemab (Leqembi) and donanemab (Kisunla), with its clinics delivering international clinical trials that helped bring these therapies into clinical practice.

These medicines mark a significant paradigm shift in Alzheimer's care, introducing disease‑modifying approaches and redefining what is possible in early intervention and treatment.

Older adults, particularly those aged 75 and over, carry a disproportionate burden of chronic disease yet remain under‑represented in clinical research. NIHR data shows that only about 15% of clinical trial participants are aged 75 or older, despite this group having high levels of multimorbidity and health needs.

This under‑representation has been highlighted by research leaders, including Professor Sir Chris Whitty and the NIHR, as a major concern because it slows the development of new treatments and means many studies do not reflect the real‑world population affected by conditions like dementia.

Additionally, recruitment into dementia trials in the UK is low compared with other disease areas, with only a small fraction of eligible people registering for studies.

Through this collaboration with Cera, Re:Cognition Health will be able to reach individuals who may not yet have accessed specialist memory services, enabling earlier referral, assessment and potential participation in clinical trials - and, where appropriate, access to new‑generation therapies at the earliest possible stage of disease.

Cera's home healthcare model, powered by technology‑enabled data capture and daily patient contact, offers a unique window into cognitive health in familiar environments. With patient consent, Cera will refer potential participants to Re:Cognition Health clinics for clinical trials they may be a match for.

Together, Re:Cognition Health and Cera will support earlier, more equitable participation in Alzheimer's research by leveraging Cera's unique scale and insight.

Cera's carers and nurses deliver technology‑enabled home healthcare visits - counting one every second on average. Through these, Cera captures real‑time, data‑driven insights into daily cognitive health, enabling the early identification of individuals who may benefit from specialist memory assessment.
This collaboration ensures that:
* Earlier identification and referral, enabling people to access specialist memory assessment and intervention at the most meaningful point in their health journey
* Equitable access to clinical trials, with participation determined solely by clinical suitability - not geography, mobility or care setting, so no one is excluded from potentially life‑changing research opportunities
* No financial barriers to participation, with studies free to join, expenses reimbursed and access to world‑leading healthcare and regular health monitoring throughout the trial
* Expert clinical oversight at every stage, with specialist neurologists and psychiatrists guiding assessment, participation and follow‑up, ensuring both safety and continuity of care

By combining home healthcare with specialist clinical expertise, this partnership empowers individuals to engage in research at the earliest opportunity, maximising the potential benefits of novel therapies while contributing to the development of the next generation of Alzheimer's treatments.

Dr Ben Maruthappu MBE, CEO and Founder of Cera, said:
"Many older adults are currently invisible to the clinical trials research system because they cannot access traditional clinic‑centric recruitment. By enabling responsible, consented identification and screening within the home, we can bridge the gap between the community and the clinic. We are offering the older generation a seat at the table of global drug discovery, ensuring that the path to a cure starts where they are most comfortable, in their own daily lives."

Dr Emer MacSweeney, CEO and Founder of Re:Cognition Health, said:
"With one in three people expected to develop dementia in their lifetime, it is essential that we create more inclusive and accessible routes into research. This collaboration enables us to extend our reach beyond traditional clinic settings and ensure that people who may benefit from early assessment and research participation are supported to do so.

Clinical trials offer individuals access to the most advanced diagnostics and emerging treatments, alongside expert medical oversight. By identifying people earlier and guiding them through every stage of their journey, we can help improve participants' experience and potential outcomes while accelerating the development of the next generation of Alzheimer's therapies."

This collaboration aligns with national priorities to improve inclusion in research and reflects a shared commitment to ensuring that advances in Alzheimer's treatment are developed with, and for, the people most affected.

# data[].attributes.attachment_link.description
Re:Cognition Health and Cera collaborate to expand access to Alzheimer's and neurodegenerative clinical trials

# data[].attributes.attachment_link.title
AstraZeneca bladder cancer therapy wins NICE backing - PharmaTimes

# data[].attributes.attachment_link.description
Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease

# data[].attributes.attachment_link.provider_name
The Pharma Navigator - Navigating The Key News Stories In Pharma

# data[].attributes.attachment_link.readable_text
The company's fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Global healthcare company, Novo Nordisk, has announced the headline results from the Phase III trial, REIMAGINE 2, which has been designed to evaluate the efficacy and safety of its fixed-dose combination treatment for obesity, CagriSema. The trial results were announced by Novo Nordisk in a Feb. 2, 2026 press release (1).

The fixed-dose treatment, CagriSema, comprises a combination of the amylin receptor agonist, Cagrilintide, and the GLP-1 receptor agonist, semaglutide. In the Phase III trial, the fixed-dose treatment was compared to two different doses of semaglutide, cagrilintide, and placebo in a cohort of 2,728 patients with type 2 diabetes inadequately controlled with metformin, either with or without an SGLT2 inhibitor.

According to the trial results, announced by Novo Nordisk, the 2.4 mg/2.4 mg fixed-combination treatment demonstrated superior HbA1c reduction and weight loss compared to semaglutide 2.4 mg after a period of 68 weeks. Additionally, the fixed-dose combination treatment demonstrated a safe and well-tolerated profile. With the vast majority of adverse events being mild to moderate and diminishing over time (1).

"We are very pleased by the clinical profile of CagriSema in type 2 diabetes patients, including a confirmation of the very strong weight loss data seen with CagriSema in the obesity trials," said Martin Holst Lange, Executive Vice President, Chief Scientific Officer and Head of Research and Development at Novo Nordisk, in the company press release (1). "By combining semaglutide and cagrilintide, we're seeing superior outcomes in both blood glucose control and weight reduction beyond those achieved with each therapy individually. The results strengthen our belief that CagriSema could be the first amylin-based combination therapy and a promising treatment option for individuals with type 2 diabetes, who also has a focus on weight loss."

Novo Nordisk has already applied for FDA approval of its fixed-dose combination treatment in December 2025 as a once weekly injection for weight management in adults (2). If approved by the U.S. regulatory authority, CagriSema will become the first injectable combination treatment to include a GLP-1 receptor agonist and amylin analogue.

"The FDA submission of CagriSema marks an important milestone and signals a new era in weight management, reinforcing Novo Nordisk's long-standing commitment to serving people living with obesity through innovation and science. Building on the well-established profile of semaglutide and combining it with a novel mechanism of action, CagriSema has the potential to represent a meaningful step forward in the holistic treatment of obesity," explained Mike Doustdar, President and CEO of Novo Nordisk, in a company press release about the regulatory submission (2)." With our leadership in metabolic disease, we are encouraged by the promise of this first-in-class combination to expand treatment options and address the evolving needs of patients."
References

1. Novo Nordisk. Novo Nordisk A/S: CagriSema Demonstrated Superior HbA1c Reduction of 1.91%-Points and Weight Loss of 14.2% in Adults with Type 2 Diabetes in the REIMAGINE 2 Trial . Press Release, Feb. 2, 2026.

2. Novo Nordisk. Novo Nordisk Files for FDA Approval of CagriSema, the First Once-Weekly Combination of GLP-1 and Amylin Analogues for Weight Management . Press Release, Dec. 18, 2025.

# data[].attributes.attachment_link.title
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment - The Pharma Navigator - Navigating The Key News Stories In Pharma

# data[].attributes.attachment_link.description
The company's fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

# data[].attributes.headline
Pancreatic cancer breakthrough - triple therapy fully regresses tumours in mice without development of resistance

# data[].attributes.subject
Pancreatic cancer breakthrough - triple therapy fully regresses tumours in mice without development of resistance

# data[].attributes.attachment_link.title
Pancreatic cancer: 3-drug combo effective in mouse models

# data[].attributes.attachment_link.description
An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

# data[].attributes.headline
Big advances in endometriosis research (finally!)

# data[].attributes.subject
Big advances in endometriosis research (finally!)

# data[].attributes.attachment_link.title
Endometriosis research shifts toward earlier diagnosis and personalized treatment

# data[].attributes.attachment_link.description
After decades of slow progress, advances in molecular profiling and organoid technology are creating new pathways for non-invasive diagnosis and targeted treatment of endometriosis.

# data[].attributes.attachment_link.title
A hidden Aloe vera compound takes aim at Alzheimer’s

# data[].attributes.attachment_link.description
Scientists have uncovered promising clues that compounds found in Aloe vera could play a role in fighting Alzheimer’s disease. Using advanced computer modeling, researchers discovered that beta-sitosterol—a natural plant compound—strongly interacts with two key enzymes involved in memory loss and cognitive decline. The compound showed stability, strong binding, and favorable safety indicators, making it a standout candidate for future drug development.

# data[].attributes.attachment_link.title
A Common Sleeping Pill May Reduce Buildup of Alzheimer’s Proteins, Study Reveals

# data[].attributes.attachment_link.description
There’s still so much we don’t know about Alzheimer’s disease, but the link between poor sleep and worsening disease is one that researchers are exploring with gusto.

# data[].attributes.attachment_link.title
Semaglutide Pill Shows Heart Benefits in One Key Group, Study Finds

# data[].attributes.attachment_link.description
Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and type 2 diabetes, a new analysis suggests.

# data[].attributes.attachment_link.title
Roche pill notches win in early breast cancer

# data[].attributes.attachment_link.description
Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the “adjuvant” setting after surgery.

# data[].attributes.attachment_link.title
Statin pills much safer than advertised, major review finds

# data[].attributes.attachment_link.description
The results, in The Lancet journal, come from trials involving more than 120,000 people comparing statins with a dummy drug or placebo.

# data[].attributes.attachment_link.title
Alcohol addiction linked to major brain gene changes

# data[].attributes.attachment_link.description
Explore the impact of alcohol addiction on brain function and how new research can guide future treatments.

# data[].attributes.attachment_link.title
‘Remnant’ Cholesterol Cut by More Than 60 Percent in New Drug Trial

# data[].attributes.attachment_link.description
Hopes are high for a powerful new compound aimed at lowering blood fat levels responsible for potentially fatal heart disease.

# data[].attributes.attachment_link.title
A bowhead whale’s DNA offers clues to fight cancer

# data[].attributes.attachment_link.description
Scientists searching for new ways to combat cancer think they may have uncovered a promising new lead in the DNA of the bowhead whale.

# data[].attributes.attachment_link.title
Scientists Find Molecular Switch That Helps Cancer Cells Defy Death

# data[].attributes.attachment_link.description
Researchers have identified a stress-activated control mechanism that helps breast cancer cells reshape gene activity to survive and grow. Cells often encounter environmental pressures that can harm or even kill them. To stay alive, they rapidly shift which genes are active so they can mount a pr

# data[].attributes.headline
Novo Nordisk sues Hims & Hers over patent infringement on weight loss drug

# data[].attributes.subject
Novo Nordisk sues Hims & Hers over patent infringement on weight loss drug

# data[].attributes.body
Novo Nordisk has their weight loss drugs patented, yet Hims & Hers is selling weight loss drugs which Novo Nordisk is saying infringes on their patent rights. This suggests the method of action may be similar between the two drugs.

https://www.ft.com/content/ea4dfb58-7f5b-49b5-bfc5-ee6f84e5369a

# data[].attributes.attachment_link.description
Access error: the page you are trying to access is unavailable. Please wait a moment and try again.

# data[].attributes.attachment_link.title
Top 10 most anticipated drug launches of 2026

# data[].attributes.attachment_link.description
Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters-albeit on an even grander scale than 2025's plenty-respectable slate of major rollouts.According to Evaluate's annual analysis of the biggest potential drug launches of the coming year, the top 10 most anticipated meds could generate a combined $45.9 billion in annual sales by 2032.

# data[].attributes.attachment_link.title
The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought

# data[].attributes.attachment_link.description
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic (semaglutide; Novo Nordisk), Wegovy (semaglutide; Novo Nordisk) and Mounjaro (tirzepatide; Eli Lilly) have been propelled to the forefront of both medical innovation and public discussion. The surging demand for GLP-1s, fuelled in part by social media amplification and celebrity endorsement, has collided with constrained […]

# data[].attributes.attachment_link.title
EU food agency sets ‘safe’ consumption level for hemp-derived CBD

# data[].attributes.attachment_link.description
The EU food safety agency indicated a safe consumption level for cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, for the first time on Monday, setting a lower bar compared with other countries such as Britain and Switzerland.

# data[].attributes.attachment_link.title
Italian nonprofit lands FDA approval for 1st gene therapy to treat rare genetic disease

# data[].attributes.attachment_link.description
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the first therapy of its kind for the rare disease and making Italy's Fondazion | Italian nonprofit Fondazione Telethon's Waskyra is an ex vivo gene therapy that can address the root genetic cause of Wiskott-Aldrich syndrome in children and adults.

# data[].attributes.attachment_link.title
A ‘Crazy’ Idea for Treating Autoimmune Diseases Might Actually Work

# data[].attributes.attachment_link.description
Lupus has long been considered incurable—but a series of breakthroughs are fueling hope.

# data[].attributes.attachment_link.title
Olive oil and bone broth: Do viral gut health foods actually work?

# data[].attributes.attachment_link.description
Many trending foods contain a “small seed of truth” but are often oversold as miracle products.

# data[].attributes.attachment_link.title
Drug trio found to block tumour resistance in pancreatic cancer models

# data[].attributes.attachment_link.description
Explore groundbreaking research on pancreatic cancer treatment that shows promise in inducing complete tumour regression.

# data[].attributes.attachment_link.title
Structural analysis reveals that water molecules mediate self-activation of GPR99 - Communications Biology

# data[].attributes.attachment_link.description
GPR99 self-activation is promoted by the second extracellular loop (ECL2) occupying the orthosteric pocket, which is stabilized by a water-mediated polar network. These findings provide a structural basis for this receptor’s physiological roles and a theoretical framework for designing drugs targeting the receptor.

# data[].attributes.attachment_link.title
Argo Biopharma doses first patient in phase 2b trial of BW‑20829 - PharmaTimes

# data[].attributes.attachment_link.description
siRNA therapeutic progresses in global study for patients with elevated Lp(a)

# data[].attributes.attachment_link.title
AI model from Google DeepMind reads recipe for life in our DNA

# data[].attributes.attachment_link.description
It could transform our understanding of why diseases develop and the medicines needed to treat them, says researchers.

# data[].attributes.attachment_link.readable_text
Prof Channa Jayasena, an expert in hormones and from Imperial College London, said: "The effect of HRT on brain health in menopause continues to be a topic of debate, and old clinical trials like the Women's Health Initiative have failed to answer this question. Either way, this is an important complication that millions of women experience in the UK, so deserves close attention in the future."

Michelle Dyson from the Alzheimer's Society said women account for around two-thirds of people living with Alzheimer's disease in the UK.

"And while we still don't fully understand why they are more susceptible than men, it is thought that hormones may play a role," she said.

"This large study adds to evidence showing how menopause impacts the brain, including physical changes such as loss of brain volume.

"But without long-term participant tracking, to check if they later develop dementia, we cannot be sure that these brain changes associated with menopause also increase dementia risk."

She said getting regular exercise, not smoking and limiting alcohol intake can help cut the risk of dementia.

# data[].attributes.attachment_link.title
Menopause linked to Alzheimer's-like brain changes

# data[].attributes.attachment_link.description
Menopause is linked to a loss of grey matter in regions involved with memory and emotion, study suggests.

# data[].attributes.attachment_link.title
Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years

# data[].attributes.attachment_link.description
Adding Merck & Co. | Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they close in on phase 3 data.

# data[].attributes.attachment_link.title
Frontiers | Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance

# data[].attributes.attachment_link.description
BackgroundVedolizumab is a gut-selective biologic widely used for inflammatory bowel disease (IBD). While randomized controlled trials (RCTs) provide initial…

# data[].attributes.attachment_link.description
The shot, given six times a year or every other month, is an alternative to taking daily pills to protect against ever catching the virus.

# data[].attributes.attachment_link.title
A new test reveals which antibiotics truly kill bacteria

# data[].attributes.attachment_link.description
Some antibiotics stop bacteria from growing without actually killing them, allowing infections to return later. Scientists at the University of Basel created a new test that tracks individual bacteria to see which drugs truly eliminate them. When tested on tuberculosis and other serious lung infections, the method revealed big differences in how bacteria tolerate treatment. The findings could lead to more precise therapies and better predictions of treatment success.

# data[].attributes.body
DOI: 10.1016/j.jep.2025.120720

# data[].attributes.attachment_link.title
A traditional Brazilian plant shows unexpected strength against arthritis

# data[].attributes.attachment_link.description
A Brazilian study has confirmed that Joseph’s Coat, a plant used for generations in folk medicine, can significantly reduce inflammation and arthritis symptoms in lab tests. Researchers observed less swelling, healthier joints, and signs of tissue protection. Just as important, the extract showed a promising safety profile at tested doses. The discovery could pave the way for new plant-based anti-inflammatory treatments.

# data[].attributes.body
Why did we choose this? Reason for 200 year lifespan and low cancer incidence in bowhead whales - potential to improve DNA repair in humans (previously thought wasn't possible, that it was already optimal) - relevant for ageing population & cancer treatment

What is it about? Researchers wanted to understand the mechanisms that underlie the cancer resistance of the bowhead whale - bowhead whale fibroblasts required fewer oncogenic hits to undergo malignant transformation than human fibroblasts. However, bowhead whale cells exhibited enhanced DNA double-strand break repair capacity and fidelity, and lower mutation rates than cells of other mammals.

What is the pharmacology component? Cold-inducible RNA binding protein (CIRBP) - protein that enhances DNA repair. Bowhead whale CIRBP enhanced both non-homologous end joining and homologous recombination repair in human cells, reduced micronuclei formation, promoted DNA end protection, and stimulated end joining in vitro. CIRBP overexpression in Drosophila extended lifespan and improved resistance to irradiation.

# data[].attributes.attachment_link.title
Evidence for improved DNA repair in long-lived bowhead whale - Nature

# data[].attributes.attachment_link.description
Analysis of the longest-lived mammal, the bowhead whale, reveals an improved ability to repair DNA breaks, mediated by high levels of cold-inducible RNA-binding protein.   

# data[].attributes.body
Q1: because HER2 is a very well known target for breast cancer and can now be used as combination therapy top treat stomach cancer and it has better performance than the Herceptin plus chemotherapy.

Q2: Large scale phase 3 trial compared with Herceptin plus chemotherapy. Compared to the control (original treatment) the risk of death decreased 28% and extends the overall survival length by 7.2-26.4 months. Although it has an increase in overall survival length, it has still not yet met the OS goal. And, the new treatment has a longer duration of response.

Q3: Old treatment binds with one region of HER2, while the new one binds with two regions. Diarrhoea is one of the adverse effects of the HER2 target therapy.

# data[].attributes.attachment_link.title
UPDATED: Jazz touts Ziihera as the new HER2 agent of choice in stomach cancer

# data[].attributes.attachment_link.description
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ Ziihera. | Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ bispecific Ziihera—at least according to two experts.

# data[].attributes.body
why:High real-world relevance

what：A 13-year-old with asthma died after repeated hospital visits where her worsening symptoms were allegedly dismissed and care wasn’t well coordinated.

component: t he mechanism of acute asthma

# data[].attributes.attachment_link.title
‘Our daughter died because her asthma was too easily dismissed’

# data[].attributes.attachment_link.description
Emily Albino, 13, died last December after an asthma attack led to a cardiac arrest.

# data[].attributes.body
why - interesting to see pill format of treatment for psoriasis

what is the article about - new pill drug for eliminating skin lesions caused by psoriasis

what is the pharmacology - envudeucitinib TYK2 blocker showing superior efficacy to competitors

# data[].attributes.attachment_link.title
Alumis soars as TYK2 drug hits mark in psoriasis trials

# data[].attributes.attachment_link.description
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

# data[].attributes.body
Group 1

1. Topical to the current climate of the world, lots of co-morbidities are associated with obesity, and many countries spend large sums of money on treating obesity itself and the co-morbidities associated with it. The advantage of non-peptide higher bioavailability. First synthetic GPL-1 type drug.

2. 72 week double blind trial that evaluates the efficacy of the drug. Showing improvements in BP, triglycerides and non-HDL cholesterol with dose-dependent weight loss as well. Safety profile was satisfactory lacking the liver toxicity that other small molecules had

3. Non- peptide agonist, harder for proteases in the stomach to break down and can survive the GI environment and reach systemic circulation without absorption enhancers. Higher bioavailability and absorption intake is not affected by food and water intake. - Binds to the transmembrane GLP-1 receptor rather than the N-terminal.

# data[].attributes.attachment_link.title
Autotaxin inhibition: unlocking new frontiers in cancers and beyond - Drug Discovery World (DDW)

# data[].attributes.attachment_link.description
Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies. Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF) faced challenges, they highlighted the complexity [...]

# data[].attributes.attachment_link.title
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication

# data[].attributes.attachment_link.description
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting | Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

# data[].attributes.attachment_link.readable_text
When Vertex Pharmaceuticals developed a treatment for genetic condition cystic fibrosis (CF), it was hailed around the world as a "groundbreaking" moment for patients.
For the first time, the condition - which often causes patients to die before their 40s, as mucus clogs and damages their lungs - could be treated at the root cause, by bypassing the genetic errors responsible for the disease.

But these treatments are thought to cost the NHS well over £100,000 a year per patient.

The newest of the so-called modulator drugs, Kaftrio, has proven effective for about 90% of CF patients - but with more than 11,000 in the UK, it would, at list price, cost the NHS more than £1bn a year.

And last month, National Institute for Health and Care Excellence (NICE) draft guidance deemed the drugs too expensive.

Patients will continue to have access to them during the appraisal process - but parents worry young children might not be eligible if NICE recommends withdrawing funding.

"Parents are right to question NICE, to make sure it has the right data to assess the drug correctly, particularly given that CF is a rare condition and that the benefits of early access might not be realised for many years or even decades," Marc Cotterill, 41, who has CF, says.

"But equally, we need to protect our NHS - its budget is limited.

"We can sit here and point the finger at NICE and assume they're trying to put a price on a life - but the problem is the price itself set by Vertex Pharmaceuticals.

"This drug has to be affordable and sustainable. It's not a one-off drug. Once on it, patients need it for life in order to enjoy the benefits."

Mr Cotterill says Kaftrio "saved" his life. And he cannot remember the last time his lung capacity was as good as it is since he started the treatment - currently, 80% functioning.

Extra cost

Other countries around the world are also arguing the price set by Vertex Pharmaceuticals for Kaftrio is too high. The US, Dutch and Canadian authorities have called for large price reductions.

But the company says it is "disappointed" by the draft NICE guidance and disagrees with some of the "key evidence that NICE has selected to use, which has a significant impact on the way that our medicines are valued, particularly underestimating the costs of caring for people with CF and the impact that CF has on a person's quality of life".

A Bristol University study, released in January, showed the average extra cost of having CF was more than £6,500 a year.

Patent law has allowed Vertex Pharmaceuticals to carefully guard its monopoly of these drugs.

But World Trade Organization agreements and national laws include flexibilities designed to ensure citizens' right to life are not threatened by intellectual-property rights - and patients are challenging the company's patents.

In February, legal papers were filed with the South African High Court, seeking a compulsory licence that would allow the supply of more affordable generic versions of the CF drug.

Petitions to revoke or suspend Vertex Pharmaceuticals' patents have also been submitted to the governments of India, Ukraine, and Brazil.

The company declined to comment on the legal processes in progress.

Vertex is running a pilot donation program to provide Kaftrio at no cost to eligible patients in 10 countries. The company says the learnings from these pilot countries will inform the future of this program.

Operating expenses

Research led by Dr Andrew Hill, of the University of Liverpool pharmacology department, found the basic production cost for these drugs was less than $6,000 (£4,790) a year per patient.

But this does not include the significant costs involved in research and development (R&D).

"The price of our medicines reflects their clinical value and benefits to patients, caregivers and healthcare systems," Vertex Pharmaceuticals told BBC News. And list prices "published at the time of marketing authorisation do not reflect the final reimbursed price agreed with the local health authorities which is confidential".

"Each year, we reinvest over $1bn into developing new medicines for people with CF, and others, who today have few or no treatment options, dedicating three out of every five Vertex employees to that purpose," the company said.

"More than 70% of our operating expenses are dedicated to R&D, well above the average of the top pharma and biotech companies in the industry."

'Hugely inflated'

Understanding the price of developing a new treatment is hugely complex.

But Diarmaid McDonald, the director of Just Treatment, which campaigns for lower-cost drugs for NHS patients and globally, says the industry should be more transparent.

"We have no idea of the real cost of clinical trials or the other costs involved in developing these drugs - though industry figures on R&D spend are criticised as hugely inflated," he says.

"We also don't really know what the NHS or other countries are paying for them or the details of the deals they are negotiating.

"It makes it really hard to judge whether we're getting value for money."

The NHS says patients already on these drugs will continue to have access to them while the negotiation continues.

But patients will nevertheless be worried about their future.

Those old enough will remember the last such process between NICE and Vertex, which involved Kaftrio's predecessor, Orkambi, another CF drug.

The negotiations lasted years and saw Vertex destroy nearly 8,000 packets of the drug, as they passed their expiry date before the price was agreed.

Buyers club

During these negotiations, the NHS called Vertex Pharmaceuticals an "extreme outlier" among pharmaceutical companies because of its hard line trying to secure a high price.

The government began discussing invoking what is known as a Crown use licence, which would have swept aside the company's exclusivity rights to these drugs and allowed the UK to buy in generic, vastly cheaper versions of the treatment.

In the end, Vertex Pharmaceuticals returned to discussions and a deal was finally agreed.

But some patients, desperate for access to these drugs in the meantime, took matters into their own hands and created a buyers club, flying to Argentina to buy a generic version produced by a company there.

In its latest financial results, Vertex Pharmaceuticals raised the amount it expects to bring in via CF product revenue to about $9.85bn.

And these results were published before the announcement the UK Medicines and Healthcare products Regulatory Agency had extended the licences of Kaftrio and Kalydeco to two- to five-year-olds, which will increase the amounts needed for NHS patients.

The second NICE committee meeting to discuss the comments submitted during the consultation period is on Thursday, with a final recommendation regarding NHS funding for these treatments expected next spring.

Vertex Pharmaceuticals says it is "committed to working collaboratively" with the NHS and NICE to secure "long-term access" for new patients who may benefit from these treatments following the conclusion of the NICE evaluation.

The company stresses that the NICE process will not impact access for patients who are already taking these medicines or who may start taking it in the near future.

"Access for these patients will continue irrespective of the outcome of the NICE process," says Vertex,

# data[].attributes.attachment_link.title
Cystic fibrosis: The miracle drugs priced out of reach

# data[].attributes.attachment_link.description
Regulators around the world have questioned the high price set by Vertex Pharmaceuticals.

# data[].attributes.body
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform

# data[].attributes.attachment_link.title
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform

# data[].attributes.attachment_link.description
InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmun…

# data[].attributes.attachment_link.title
NHS England » NHS to roll out first long-acting injection to prevent HIV

# data[].attributes.attachment_link.description
NHS England » NHS to roll out first long-acting injection to prevent HIV

# data[].attributes.attachment_link.title
Harmful mouth bacteria may trigger Parkinson’s disease

# data[].attributes.attachment_link.description
A familiar mouth bacterium best known for causing cavities may also be quietly influencing the brain. Scientists found that when this microbe settles in the gut, it produces compounds that can travel through the bloodstream and harm neurons involved in movement. In animal studies, this process triggered inflammation, motor problems, and brain changes linked to Parkinson’s disease. The findings hint that protecting oral and gut health could help protect the brain as well.

# data[].attributes.attachment_link.title
Newly discovered coffee compounds beat diabetes drug in lab tests

# data[].attributes.attachment_link.description
Roasted coffee may do more than wake you up—it could help control blood sugar. Researchers discovered several new coffee compounds that inhibit α-glucosidase, a key enzyme linked to type 2 diabetes. Some of these molecules were even more potent than a common anti-diabetic drug. The study also introduced a faster, greener way to uncover health-boosting compounds in complex foods.

# data[].attributes.headline
GROUP 6: Chinese Scientists Develop “Bone Glue” for Shattered Fractures

# data[].attributes.subject
GROUP 6: Chinese Scientists Develop “Bone Glue” for Shattered Fractures

# data[].attributes.attachment_link.title
Chinese Scientists Develop “Bone Glue” for Shattered Fractures

# data[].attributes.attachment_link.description
Researchers in China design a novel bone adhesive that bonds and heals shattered bone fragments, showing over twice the performance of traditional fixatives in animal models.

# data[].attributes.headline
FDA rejects expansion of Jet Lag Disorder drug, quoting inadequate evidence

# data[].attributes.subject
FDA rejects expansion of Jet Lag Disorder drug, quoting inadequate evidence

# data[].attributes.body
Vanda Pharmaceuticals

# data[].attributes.attachment_link.title
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

# data[].attributes.attachment_link.title
Less than two years after stopping obesity drugs, weight and health issues return, study finds

# data[].attributes.attachment_link.description
The retrospective study could not determine whether some patients were more likely than others to keep off the weight.

# data[].attributes.headline
HIV can develop resistance to the breakthrough drug lenacapavir

# data[].attributes.subject
HIV can develop resistance to the breakthrough drug lenacapavir

# data[].attributes.attachment_link.title
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication

# data[].attributes.attachment_link.description
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting | Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

# data[].attributes.attachment_link.title
GSK, Ionis claim study success for RNA-based hepatitis B drug

# data[].attributes.attachment_link.description
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

# data[].attributes.attachment_link.title
Inside Health - Can we reverse rising drug deaths? - BBC Sounds

# data[].attributes.attachment_link.description
We try to figure out why drug deaths are at an all-time high - and what can be done.

# data[].attributes.attachment_link.title
What will be the first AI-designed drug? These disease-fighting antibodies are top contenders

# data[].attributes.attachment_link.description
Just a year after the first AI-designed antibody was made, scientists say clinical trials are on the horizon.

# data[].attributes.attachment_link.title
Immune system changes affecting sensory nerves could cause fibromyalgia | King’s College London

# data[].attributes.attachment_link.description
Fibromyalgia might be caused by changes in the body’s immune system which alter nerve cells in the skin.

# data[].attributes.attachment_link.title
Will mpox go global again? Research shows it’s evolving in curious ways

# data[].attributes.attachment_link.description
Analyses of mpox clades currently in circulation provide clues to how the virus managed to spread worldwide in 2022 — and how it might go global again.

# data[].attributes.attachment_link.title
FDA cites severe liver injury risk, unclear benefit behind Sanofi’s MS drug rejection

# data[].attributes.attachment_link.description
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns—including a | Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns, including a case of serious liver injury that led to death.

# data[].attributes.attachment_link.title
Pain, Pus and Poison: The Search for Modern Medicines

# data[].attributes.attachment_link.description
Michael Mosley tells the story of the creation of our most useful and valuable drugs.

# data[].attributes.attachment_link.title
AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo

# data[].attributes.attachment_link.description
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive pha | AstraZeneca, chasing GSK’s rival Benlysta, is looking to bring a subcutaneous version of its 2021-approved Saphnelo to more patients after nabbing a European nod last month.